These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26636658)

  • 41. Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.
    Elvebakken H; Venizelos A; Perren A; Couvelard A; Lothe IMB; Hjortland GO; Myklebust TÅ; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Knappskog S; Sorbye H
    Br J Cancer; 2024 Sep; 131(4):676-684. PubMed ID: 38909137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paclitaxel-carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series.
    Kotaka S; Kondo E; Kawai Y; Okamoto K; Kishigami Y; Yamawaki T; Nagao K; Toru H; Suzuki S
    J Obstet Gynaecol Res; 2023 Dec; 49(12):2868-2874. PubMed ID: 37658751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
    Zhang P; Li J; Li J; Zhang X; Zhou J; Wang X; Peng Z; Shen L; Lu M
    Cancer; 2020 May; 126 Suppl 9(Suppl 9):2086-2092. PubMed ID: 32293725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
    Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
    Thiery-Vuillemin A; Dobi E; Nguyen T; Royer B; Montange D; Maurina T; Kalbacher E; Bazan F; Villanueva C; Demarchi M; Chaigneau L; Ivanaj A; Pivot X
    Anticancer Drugs; 2010 Nov; 21(10):958-62. PubMed ID: 20856105
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Kalman L; Castine M; Sylvester L; Greco FA
    Gynecol Oncol; 2005 Apr; 97(1):200-5. PubMed ID: 15790459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
    Nakano K; Takahashi S; Yuasa T; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Tsuyama N; Ishikawa Y; Hatake K
    Jpn J Clin Oncol; 2012 Aug; 42(8):697-703. PubMed ID: 22701038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
    Abdel-Rahman O; Koski SL
    Neuroendocrinology; 2022; 112(8):777-783. PubMed ID: 34649258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Poorly-differentiated neuroendocrine carcinoma of ascending colon with liver metastases successfully treated with carboplatin and etoposide].
    Akiyama S; Niitani T; Narasaka T; Ohto T; Gamoh M
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1209-12. PubMed ID: 21772114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
    Hadoux J; Walter T; Kanaan C; Hescot S; Hautefeuille V; Perrier M; Tauveron I; Laboureau S; Do Cao C; Petorin C; Blanchet O; Faron M; Leteurtre E; Rousselet MC; Joubert Zakeyh J; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Lombard-Bohas C; Ducreux M; Scoazec JY; Baudin E; ;
    Endocr Relat Cancer; 2022 Oct; 29(10):569-580. PubMed ID: 35920609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
    Govindan R; Wang X; Baggstrom MQ; Burdette-Radoux S; Hodgson L; Vokes EE; Green MR;
    J Thorac Oncol; 2009 Feb; 4(2):220-6. PubMed ID: 19179900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma.
    Tonder M; Weller M; Eisele G; Roth P
    Chemotherapy; 2014; 60(5-6):375-8. PubMed ID: 26496463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
    Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
    Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma.
    Agatsuma T; Koizumi T; Kanda S; Ito M; Urushihata K; Yamamoto H; Hanaoka M; Kubo K
    J Thorac Oncol; 2011 Dec; 6(12):2130-4. PubMed ID: 21892103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.